Sabbin magungunan likita da ake kira ciwon kwantar da hankalin da aka yi niyya suna samun samuwa ga ciwon huhu. Ba kamar maganin gargajiya na gargajiya ba, waɗannan jiyya sun sa sunadaran sunadarai a kan kwayoyin cutar kanjamau ko ƙwayoyin da ke cikin al'amuran al'ada waɗanda kwayar cutar ta rushe a cikin ƙoƙari na girma. Saboda wannan dalili, sun kasance suna da nauyin illa mai yawa da yawancin magunguna da aka yi amfani da su don ciwon daji.
A halin yanzu, ana amfani da su ne don ciwon daji na 3 da 4 na huhu wanda bai amsa wa sauran jiyya ba . Biyu daga cikin hanyoyin maganin da aka fi sani da sun hada da:
Tarceva (erlotinib)
An gano nau'in kwayar cutar ciwon huhu a jikin mahaifa da ake kira epidermal growth factor receptor (EGFR) , wanda zai taimaka wa rabuwa su raba. Tarbava aiki ne ta hanyar ba da izinin EGFR don gaya wa kwayoyin cutar kanjamau suyi girma. Ko da yake yana da tasiri sosai a yawancin marasa lafiya, an nuna cewa zai iya yin aiki ga waɗanda basu taɓa shan taba ba ko kuma a cikin ƙananan mata. Ba a matsayin kwaya na yau da kullum, sakamakon da yafi kowa a cikin jiki shi ne fatar jiki mai kama da kuraje, da kuma zawo. Kodayake fatawar fata zai iya kasancewa rashin lafiya, wadanda suke ci gaba da raguwa da erlotinib sun fi dacewa su amsa maganin.
Xylori (Crizotinib)
Daga tsakanin 3 zuwa 5% na mutanen da marasa ciwon huhu na huhu ba su da wani maye gurbin da aka sani da gyara ALK-EML4.
Ga mutanen da wannan maye gurbin, an gano crizotinib na magani don ƙara yawan rayuwa mai ci gaba. Kamar dai yadda erlotinib yake, crizotinib sau da yawa yana da nau'in illa mafi yawa fiye da chemotherapy na gargajiya kuma ana iya ɗauka a matsayin magani na maganin. Hakazalika, wannan maye gurbin idan akwai yiwuwar samuwa a cikin mutanen da basu taba taba taba taba ba.
Duk da yake crizotinib yana kara tsawon rayuwa, babu shakka, juriya yakan tasowa a lokaci. Abin godiya an gano sababbin magunguna a gwaji na gwaji wanda zai iya aiki yayin da tsayayya ga crizotinib ya tasowa, kuma ana fatan cewa a lokacin, cutar mai cututtuka ta ALK za a iya magance shi kamar cutar ciwon daji, irin su ciwon sukari.
Ƙara koyo game da ciwon daji na ALK-tabbatacce a cikin wannan labarin
Tun daga shekarar 2014, an yarda da crizotinib ga mutane da maye gurbin ROS1 . Kamar wadanda suke tare da maye gurbin ALK, crizotinib yana ƙara cigaba da rayuwa.
Wasu magunguna ne a halin yanzu an kimantawa a gwaji na asibiti ga mutanen da suka zama magunguna ga magunguna don maye gurbin EGFR da maye gurbin ALK, da sauran "maye gurbi" ana nazarin.
Nazarin Halitta (Farfesa na Lafiyar Lafiyar) Domin Ciwon Cutar Kwala
A halin yanzu an ji cewa duk wanda ke da ciwon ƙwayar cuta mai cike da ƙwayar cuta (kuma wasu mutanen da ke fama da ciwon huhu na mahaifa , musamman ma waɗanda basu taɓa shan taba ba) ya kamata a gwada su don maye gurbin mutun da yiwuwar cewa ƙwayarwarsu za su amsa da magungunan sababbin magunguna. Duk da haka, mutane da yawa waɗanda suke da tabbas ga waɗannan maye gurbi da kuma masu goyon baya ga waɗannan magunguna, ba su sami amfanin gwaji.
Ƙara koyo game da labarun kwayoyin cutar kanjamau a wannan labarin
> Sources:
> Cibiyar Ciwon Ƙwayar Yammacin Amirka. Magunguna da aka ƙayyade. 08/13/15.
> Cibiyar Cancer ta Kasa. Ƙananan ƙwayar ƙwayar ƙwayar cuta ta jiki (PDQ). Jiyya Option Overview. Updated 05/12/15.